104 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
8 May 24
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
4:05pm
trials further demonstrate breadth and durability of STARR® vaccine platform
ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data … containing the Omicron XBB.1.5 variant.
The purpose of this study is to generate additional immunogenicity and safety data to support product licensure
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
19 Mar 24
Regulation FD Disclosure
6:00am
) for booster vaccination conducted in Japan.
In the phase III clinical study, immunogenicity and safety of a bivalent version of Kostaive® (ARCT-2301 … and Wuhan strain). There were no causally-associated severe or serious adverse events with ARCT-2301.
These results support immunogenicity and safety
8-K
EX-99.1
lyyzbes3
7 Mar 24
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
4:05pm
8-K
EX-99.1
ohjt 62rezc6h4sc
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
8-K
EX-99.1
ikmaq47l68y8ovku
26 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-99.1
c7yq3
7 Aug 23
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
4:23pm
8-K
o9gf26gol5 yozus9
14 Jul 23
Regulation FD Disclosure
7:53am
8-K
EX-99.1
t1yebdlb3jhskfl
30 Jun 23
Regulation FD Disclosure
8:28am
8-K
EX-99.1
hs9sk k13wml
9 May 23
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
4:11pm
8-K
EX-99.1
mm2gb r2qb
28 Apr 23
Regulation FD Disclosure
6:00am